# Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib

> **NCT00203424** · PHASE2 · COMPLETED · sponsor: **Translational Oncology Research International** · enrollment: 23 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Erlotinib + Bevacizumab

## Key facts

- **NCT ID:** NCT00203424
- **Lead sponsor:** Translational Oncology Research International
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2009-02
- **Final completion:** 2010-06
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2016-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00203424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00203424, "Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00203424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*